American Heart Association Scientific Sessions 2014
News from AHA Scientific Sessions 2014 More from ODYSSEY: ODYSSEY COMBO, OPTIONS I and OPTIONS II
More from ODYSSEY: ODYSSEY COMBO, OPTIONS I and OPTIONS II add to the picture for alircoumab in managing high to very high cardiovascular risk patients ODYSSEY COMBO I This trial included 316 hypercholesterolaemic patients at high cardiovascular risk (mean age 63 years, 63-72% male, 78%…
read more »
More from ODYSSEY: ODYSSEY High FH
More from ODYSSEY: In ODYSSEY High FH, FH patients poorly controlled on maximally tolerated lipid-lowering therapy (including statin) achieved a 46% reduction in LDL-C levels with alirocumab 150 mg every 2 weeks. ODYSSEY High FH included 107 patients (mean age 50-52 years, 49-63% male) with…
read more »
News from AHA Scientific Sessions 2014 More from ODYSSEY: ODYSSEY LONG TERM
More from ODYSSEY: ODYSSEY LONGTERM, the largest double-blind study of a PCSK9 inhibitor, continues to show a favourable efficacy/safety profile for alirocumab. The ODYSSEY LONG TERM trial included 2,341 patients with hypercholesterolaemia (both with familial hypercholesterolaemia [FH] and non-FH) with a baseline LDL-C 70 mg/dL…
read more »
AHA Scientific Sessions 2014: The Editors view of Day 2
PCSK9 Forum Editor Professor Derick Raal, University of the Witwatersrand, South Africa, discusses posters presented to date. Since the arrival of the PCSK9 inhibitors, there has been a resurgence of interest in lipids in the poster sessions with a dedicated “lipid lane” which was very…
read more »
AHA Scientific Sessions – TAUSSIG analysis: Homozygous FH patients on lipid apheresis
Treatment with PCSK9 monoclonal antibody therapy results in further LDL-C lowering in patients with homozygous familial hypercholesterolaemia (FH ) receiving lipid apheresis, provided that they have at least one LDL receptor-defective mutation, according to data from the Trial Assessing Long-Term Use of PCSK9 Inhibition in…
read more »
AHA Scientific Sessions 2014: The Editors view of Day 1
PCSK9 Forum Editor Professor Derick Raal, University of the Witwatersrand, South Africa, discusses the take home messages from the Day 1 Latebreaker Trials IMPROVE-IT After much debate, IMPROVE-IT showed a significant benefit – although only just – with 6.4% reduction (p=0.016) in the primary outcome…
read more »
News from AHA Scientific Sessions Latebreakers IMPROVE-IT: support for the lower is better hypothesis
Results from IMPROVE-IT reaffirm the LDL hypothesis that ‘lower is better’. As incremental benefit on cardiovascular outcomes was seen with the addition of non-statin therapy, IMPROVE-IT bodes well for the PCSK9-targeted therapies. The IMPROVE-IT trial has been the subject of much speculation over the last…
read more »
News from AHA 2014 ODYSSEY ALTERNATIVE in statin-intolerant patients
Alirocumab shows efficacy in statin intolerant patient with fewer muscle-related adverse events than atorvastatin. There was virtually no myalgia among patients who continued on open-label alirocumab, reinforcing that the fear of allocation to statin has had an enormous effect in the blinded study phase. Statin…
read more »
